Abbott (ABT) Reiterated Buy at Citi on Strong Glucose Monitoring Growth

Key Facts

1Citigroup reiterated its 'Buy' rating for Abbott Laboratories, estimating fair value between $99 and $104.

2The company anticipates approximately $3 billion in incremental sales for 2026 following its acquisition of Exact Sciences.

3Continuous glucose monitoring (CGM) sales increased by 7.5% to $2.00 billion in the first quarter.

Amid a shifting landscape in healthcare technology, Citigroup has reiterated its 'Buy' rating for Abbott Laboratories, estimating the stock's fair value between $99 and $104. This bullish stance is supported by a 7.5% increase in continuous glucose monitoring (CGM) sales, which reached $2.00 billion in the first quarter. Furthermore, the company anticipates approximately $3 billion in incremental sales by 2026, following its strategic acquisition of Exact Sciences.

The valuation reflects optimism regarding Abbott's growth trajectory compared to its healthcare peers, particularly in the high-growth diagnostics segment. In the broader financial context, Citigroup (C) shares closed at $141.21 on June 15, 2026, while JPMorgan (JPM) stood at $336.03 on June 17, 2026, per market data. Analysts suggest that Abbott remains structurally undervalued relative to its long-term revenue potential from cancer diagnostics and diabetes care.

Traders should watch the current price action as ABT closed at $90.62 on June 16, 2026, suggesting potential upside toward the analyst price targets. Upcoming catalysts include the Michigan Consumer Sentiment index on June 12, which serves as a key indicator of US consumer health and spending capacity in the medical device sector.